The autologous serum skin test (ASST) predicts the response to anti-IgE treatment in Chronic Spontaneous Urticaria patients: a prospective study
Conclusions. Although larger prospective studies are needed to confirm these results, this study confirms previous retrospective investigations that the positive ASST appears to predict a slow response to omalizumab in CSU patients.PMID:38482859 | DOI:10.23822/EurAnnACI.1764-1489.337 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - March 14, 2024 Category: Allergy & Immunology Authors: A Palladino F Villani E Pinter M Visentini R Asero Source Type: research
Who are the potential patients for Omalizumab for Food Allergy?
Ann Allergy Asthma Immunol. 2024 Mar 11:S1081-1206(24)00147-9. doi: 10.1016/j.anai.2024.03.006. Online ahead of print.NO ABSTRACTPMID:38479711 | DOI:10.1016/j.anai.2024.03.006 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - March 13, 2024 Category: Allergy & Immunology Authors: Hugh A Sampson J Andrew Bird David Fleischer Wayne G Shreffler Jonathan Spergel Source Type: research
Who are the potential patients for Omalizumab for Food Allergy?
Ann Allergy Asthma Immunol. 2024 Mar 11:S1081-1206(24)00147-9. doi: 10.1016/j.anai.2024.03.006. Online ahead of print.NO ABSTRACTPMID:38479711 | DOI:10.1016/j.anai.2024.03.006 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - March 13, 2024 Category: Allergy & Immunology Authors: Hugh A Sampson J Andrew Bird David Fleischer Wayne G Shreffler Jonathan Spergel Source Type: research
Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization : Results of a multicentric study
CONCLUSION: Add-on biologic therapy is effective, safe, and widely accepted among CRSwNP + NERD patients. Future studies might allow for personalized algorithms with sequential surgery, ATAD, and/or biologic therapy.PMID:38466409 | DOI:10.1007/s00106-024-01433-y (Source: HNO)
Source: HNO - March 11, 2024 Category: ENT & OMF Authors: Anna-Rebekka Staufenberg Hanna K Frankenberger Ulrike F örster-Ruhrmann Franziska C Spahn Ludger Klimek Kai Fruth Clemens Stihl Christoph Matthias Moritz Gr öger Jan Hagemann Source Type: research
Who are the potential patients for Omalizumab for Food Allergy?
Food allergies affect an estimated 8% of the United States population and have risen significantly in the last 20 years.1 IgE-mediated reactions to food can range from simple urticaria to life-threatening anaphylaxis. The only treatment was avoidance of the allergen and treatment of allergic reactions with epinephrine until 2020, when an oral immunotherapy (OIT) product (Palforzia) was approved for the treatment of peanut allergy.2 There was no FDA approved treatment for other foods or multiple foods until the recent approval of omalizumab for any food allergy for patients 1 years of age or older with the appropriate total...
Source: Annals of Allergy, Asthma and Immunology - March 11, 2024 Category: Allergy & Immunology Authors: Hugh A. Sampson, J. Andrew Bird, David Fleischer, Wayne G. Shreffler, Jonathan Spergel Tags: Perspective Source Type: research
